• SECN-15 represents promising new therapeutic strategy to enhance anti-tumor immunity and overcome resistance to checkpoint inhibitors
• Preclinical data demonstrate strong anti-tumor efficacy in monotherapy as well as in combination therapy setting
• Translational data confirm gastric cancer as one of the lead indications for planned clinical Phase I/II trial

Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced that preclinical data for its proprietary antisense oligonucleotide (ASO) SECN-15 will be presented in a poster session at the 40th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD, USA, on Friday, November 7, 2025.

Poster Highlights
The poster outlines the potential of SECN-15 as a high-affinity ASO designed to selectively downregulate Neuropilin-1 (NRP1) expression, a promising target in oncology with the potential to break resistance to immune checkpoint inhibitors (ICIs). Elevated NRP1 expression correlates with poor prognosis across multiple solid tumors and is associated with epithelial-mesenchymal transition (EMT), angiogenesis, fibrosis and the establishment of an immunosuppressive tumor microenvironment – key processes that drive tumor progression and resistance to currently approved immunotherapies. 

• The companies will jointly develop a first-in-class disease-modifying oligonucleotide against a newly validated target relevant for rare genetic disorders as well as broader disease conditions
• Collaboration will leverage expertise and synergies of both companies’ platforms to bring new treatments to patients

Martinsried (Munich), Germany, October 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the signing of an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases. The agreement covers the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform.

Secarna will lead the oligonucleotide discovery part of the collaboration, bringing OligoCreator®, its proprietary AI-empowered oligonucleotide discovery and development platform, to the co-development. OligoCreator® has been shown to greatly expedite the drug discovery process, from target selection to therapeutic development, identifying and characterizing potentially safe and efficacious therapeutic candidates at unparalleled speed. Within the collaboration, Secarna will utilize its platform to identify promising candidates, while Scenic will add its expertise on target and disease biology.

• Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases

Martinsried (Munich), Germany, and Zurich, Switzerland, September 30, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.(NASDAQ:VACH, “Voyager”), today announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs). The combination of both technology platforms aims to unlock novel targeted therapies for the treatment of autoimmune and chronic immune diseases.